CommercialCoverageMedium impact
08.02.53a, Belantamab mafodotin-blmf (Blenrep)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Policy 08.02.53a for Belantamab mafodotin-blmf (Blenrep) has been updated effective July 1, 2026. This is a pharmacy policy for a monoclonal antibody used in multiple myeloma treatment. Without access to the full policy text details, the specific coverage changes, prior authorization requirements, or billing code updates cannot be determined from the provided information.
Action Required
By June 15, 2026: Billing team must review the complete updated policy text at the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-08-02-53a) to identify specific billing codes, prior authorization requirements, and coverage criteria for Blenrep. Update billing system rules, prior authorization workflows, and provider documentation templates accordingly before the July 1, 2026 effective date. Notify oncology and hematology providers of any changes to ensure compliant billing and minimize claim denials.